Upcoming Data Presentations for BRIUMVI
TG Therapeutics, Inc. (NASDAQ: TGTX) has unveiled an exciting schedule of data presentations that will take place at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting. This event, focused on BRIUMVI (ublituximab-xiiy), aims to provide valuable insights for patients dealing with relapsing forms of multiple sclerosis (RMS). The meeting is set for September 18 to 20, serving as a key platform for sharing important clinical trial findings.
Key Presentation Highlights
The data presented will highlight results from the ULTIMATE I & II Phase 3 trials, along with insights from the ENHANCE Phase 3b trial. These studies assess the effectiveness and tolerability of BRIUMVI, providing essential information for both clinicians and patients about the progression of MS treatments.
Below is the schedule of presentations, including their focus and timing:
Poster Presentation Details
Title: Five years of Ublituximab in relapsing multiple sclerosis: additional results from open-label extension of ULTIMATE I and II studies
Date/Time: Wednesday, September 18 at 16:15 – 18:15 CEST
Session: Poster Session 1 – Room D3
Abstract Number: Abstract 2102/P324
Lead Author: Dr. Bruce Cree from the Weill Institute for Neurosciences.
Title: Efficacy and tolerability of ublituximab after transitioning from different therapies: Updates from the ENHANCE study
Date/Time: Wednesday, September 18 at 16:15 – 18:15 CEST
Session: Poster Session 1 – Room D3
Abstract Number: Abstract 2259/P329
Lead Author: Dr. John Foley from Rocky Mountain Multiple Sclerosis.
Title: Comparison of Multiple Sclerosis Disease Activity Test results between Ublituximab and Teriflunomide
Date/Time: Wednesday, September 18 at 08:00 CEST
Session: ePoster
Abstract Number: Abstract 1382/eP1516
Lead Author: Dr. John Foley.
Availability of Data
After the presentations, the data will be made available on TG Therapeutics' website in the Publications section, providing a valuable resource for healthcare professionals and anyone interested.
Understanding BRIUMVI
BRIUMVI is a distinctive monoclonal antibody that specifically targets CD20-expressing B-cells, which play a vital role in treating autoimmune diseases like RMS. Its innovative glycoengineering distinguishes it from other treatments by minimizing sugar molecules, allowing for effective B-cell depletion at lower doses. This approach aims to enhance treatment efficacy while reducing potential side effects.
Clinical Trials Overview
The ULTIMATE I & II trials involved 1,094 patients over a period of 96 weeks, comparing the effectiveness of BRIUMVI with teriflunomide. Key criteria for selection included prior relapses and specific disability statuses, focusing on a population in need of advanced therapeutic options.
Moreover, the safety profile of BRIUMVI has been carefully evaluated. Although infusion reactions were noted, appropriate monitoring and premedication have been shown to effectively reduce the incidence of severe reactions during the clinical trials.
Patient Support Initiatives
TG Therapeutics is dedicated to supporting patients beyond just providing treatment. The BRIUMVI Patient Support program offers tailored resources to assist patients throughout their treatment journey, ensuring they have access to all necessary support during their therapy.
Frequently Asked Questions
What is BRIUMVI?
BRIUMVI is an innovative monoclonal antibody designed to treat relapsing forms of multiple sclerosis by targeting CD20-expressing B-cells.
When will the ECTRIMS meeting occur?
The ECTRIMS annual meeting will be held from September 18 to 20, 2024.
What presentations will TG Therapeutics showcase?
TG Therapeutics will present data from the ULTIMATE I & II trials and the ENHANCE study on the efficacy and tolerability of ublituximab.
How can I access the presented data?
The data will be available on the Publications page of the TG Therapeutics website following the presentations.
Where can I find more information about the company?
You can visit TG Therapeutics' official website at www.tgtherapeutics.com for comprehensive company insights and updates on their research and support programs.
